Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Wave Life Sciences (NASDAQ:WVE) stands against other biggest ...

Opens in a new tab or window SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences ...

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with ...

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. One of the key players, Avidity ...

GRAND RAPIDS, Mich. (WOOD) — People hit the road for a short race Saturday to support research into Duchenne muscular dystrophy. The GR .1K was held Saturday afternoon on Bridge Street.

Patients with Duchenne muscular dystrophy (DMD) have long been without effective treatment options. Longstanding treatments such as corticosteroids and exon-skipping therapies can prolong the time it ...